Wuhan Wuyao Pharmaceutical Co., Ltd.

Wuhan Wuyao Pharmaceutical Co., Ltd. is a wholly-owned holding subsidiary invested and established by Grand Pharma (China) Co., Ltd. in 2002. It is a well-known high-tech enterprise in China specializing in the production of characteristic active pharmaceutical ingredients. Its current production sites are located in Grand Industrial Park, Fuchi Town, Yangxin County, Huangshi City, Hubei Province, and Dingliu Village, Longhuashan Subdistrict, Xiantao City, Hubei Province.
The company currently has 850 employees, including 500 technical and management personnel with college degrees or above. The company has a registered capital of 61 million yuan and annual sales revenue of 600 million yuan. Its products are exported to more than 40 countries and regions in Europe and America, with an annual export value of 50 million US dollars.
Since its establishment, the company has adhered to the principle of "improving good products, cultivating high realms," developing from bulk active pharmaceutical ingredients to characteristic active pharmaceutical ingredients, and abiding by the core values of "providing good products, cultivating high realms." Following the development direction of product operations, its main product series include ophthalmology, cardiovascular, antibacterial and anti-inflammatory, antipyretic and analgesic, and hepatoprotective products. Among them, enoxacin is a Class II new drug after the promulgation of China's Drug Administration Law; tirofiban hydrochloride is a project under the national "Torch Plan"; pirenoxine sodium and norepinephrine bitartrate series products are specially approved for production nationwide; and multiple products such as dimercaprol have been rated by the industry as "conscience drugs" and "reassuring drugs." With its profound historical accumulation, the company has long been designated as a national emergency reserve drug and narcotics enterprise. It is also a key active pharmaceutical ingredient supplier for critical drug industry chains, including epidemic prevention and control clinical emergency drugs, drugs selected in national centralized procurement, and livelihood-supporting drugs listed in the medical insurance catalog. Among them, epinephrine (commonly known as "cardiotonic injection"), hydroxychloroquine, metronidazole, and methoxamine hydrochloride are listed as anti-epidemic drugs.
With the vision of "becoming a pharmaceutical company respected by Chinese doctors and patients, and giving back to society," the enterprise has formulated a medium- and long-term development plan for the future, advancing in a step-by-step manner the transformation and upgrading of traditional bulk active pharmaceutical ingredient products, accelerating R&D breakthroughs and technological innovation, and focusing on developing emergency drug product series. It focuses on breaking through the bottleneck of small-variety drugs, optimizing characteristic active pharmaceutical ingredient products, strengthening the volume of bulk active pharmaceutical ingredients, upgrading the scale of international trade, extending the industrial chain, integrating resources, and achieving synergistic fusion to create an intermediate--active pharmaceutical ingredient--formulation full-industrial-chain ecological layout. It focuses on developing characteristic small-variety drugs (shortage drugs), accelerating the construction of production bases for small-variety drugs (shortage drugs), accelerating the integration layout of active pharmaceutical ingredients and formulations, building technical barriers, forming core competitiveness, supporting the long-term development of the enterprise, coordinating the implementation of the enterprise's strategic planning, and striving to build itself into a green benchmark enterprise for Chinese active pharmaceutical ingredients and a well-known global supply base for active pharmaceutical ingredients.